主动清除血肿与预防迟发性脑缺血治疗降低动脉瘤性蛛网膜下腔出血患者的分流依赖性脑积水
BACKGROUND AND OBJECTIVES: Chronic shunt-dependent hydrocephalus (CSH) is a common and serious complication after aneurysmal subarachnoid hemorrhage (aSAH).…
要点
- ABCD治疗可降低aSAH患者分流依赖性脑积水的发生率。
- 高血负荷患者(Hijdra评分30-42)从ABCD治疗中获益更显著。
- Hijdra评分是标准治疗组脑积水的预测因素,但在ABCD组无此关联。
核心结论
- 接受ABCD治疗的aSAH患者分流依赖性脑积水发生率显著低于匹配对照组。
- ABCD治疗可能是重型蛛网膜下腔出血患者的重要预防策略。
研究设计与样本
- 匹配配对分析,纳入160例接受ABCD治疗的aSAH患者与160例对照。
- 配对基于WFNS分级、年龄、脑疝、脑内出血和初始Hijdra评分的最佳拟合模型。
- 按Hijdra评分分层以考虑血负荷。
主要发现
- 较低Hijdra评分患者中未观察到显著效果。
关键数值与推荐
- ABCD治疗使用鞘内尿激酶和尼莫地平灌洗。
- CSH发生率比较采用χ2检验,时间至分流依赖性脑积水采用多变量病因特异性Cox比例风险模型。
- 多变量逻辑回归用于识别脑积水预测因素。
临床怎么用
- 对于aSAH患者,尤其是高血负荷(Hijdra 30-42)者,可考虑ABCD治疗以降低分流依赖性脑积水风险。
- Hijdra评分可用于识别可能从ABCD治疗中获益的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Chronic shunt-dependent hydrocephalus (CSH) is a common and serious complication after aneurysmal subarachnoid hemorrhage (aSAH). Active blood clearance and delayed cerebral ischemia prevention (ABCD) therapy, using intrathecal urokinase and nimodipine irrigation, aims to enhance blood clearance and prevent vasospasm. This study evaluates whether ABCD therapy reduces the incidence of CSH in aSAH patients. METHODS: A matched-pairs analysis was performed and 160 aSAH patients who had received ABCD therapy were compared with 160 controls. Patients were paired on the basis of a best fit model including the World Federation of Neurological Surgeons grade, age, cerebral herniation, intracerebral hemorrhage, and the initial Hijdra score. Patients were stratified by Hijdra score to account for blood load. The incidence of CSH was compared between groups using χ 2 tests, whereas a multivariable cause-specific Cox proportional hazards model was used to assess time to shunt-dependent hydrocephalus. In addition, multivariate logistic regression was performed to identify predictors of hydrocephalus. RESULTS: The incidence of CSH was significantly lower in the ABCD group (19.4%) compared with the standard care group (31.3%, P = .015). Subgroup analysis revealed that patients with the highest blood load (Hijdra 30-42) experienced a significant reduction in hydrocephalus (45.8% vs 22.5%, P = .026). By contrast, no significant effects were observed in patients with lower Hijdra scores. Multivariate analysis confirmed that the Hijdra score was a significant predictor of CSH in the standard care group ( P = .008) but not in the ABCD-treated group ( P = .843). CONCLUSION: aSAH patients selected for ABCD therapy had a significantly lower incidence of shunt-dependent hydrocephalus compared with matching controls. ABCD therapy may be an important preventive strategy in patients with severe subarachnoid hemorrhage.
引用
- Overstijns M, Csók I, Bissolo M, et al. Active Blood Clearance and Delayed Cerebral Ischemia Prevention Therapy Reduces Shunt-Dependent Hydrocephalus in Patients With Aneurysmal Subarachnoid Hemorrhage. Neurosurgery. 2025. PMID: 41020601. doi:10.1227/neu.0000000000003756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。